[EN] PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER [FR] DÉRIVÉS DE PURINE EN TANT QU'INHIBITEURS DE CD73 POUR LE TRAITEMENT DU CANCER
[EN] PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER [FR] DÉRIVÉS DE PURINE EN TANT QU'INHIBITEURS DE CD73 POUR LE TRAITEMENT DU CANCER
Realisation of highly stereoselective dihydroxylation of a cyclopentene in the synthesis of (−)-aristeromycin
作者:Yuko Tokoro、Yuichi Kobayashi
DOI:10.1039/a901819k
日期:——
A 2-furyl group was used as a synthetic equivalent of the CH2OH at the 4â² position of aristeromycin, and dihydroxylation of the cyclopentene possessing the furyl group proceeded highly stereoselectively to produce the key diol for the synthesis of (â)-aristeromycin.
Purine derivatives as CD73 inhibitors for the treatment of cancer
申请人:Vitae Pharmaceuticals, Inc.
公开号:US10654884B2
公开(公告)日:2020-05-19
Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
Dihydroxylation of 4-aryl-1-azido-2-cyclopentenes 6, in which an aryl group is used as a synthetic equivalent of CH2OH, was studied to improve the low to moderate stereoselectivity previously reported for cyclopentenes 3 possessing CH2X and nitrogen atom-containing groups. 2-Furyl, Ph, and p-MeOC6H4 groups were chosen as the aryl groups. Compounds 6a-c possessing such aryl groups were prepared by CuCN-catalyzed reaction between 2-cyclopentene-1,4-diol monoacetate 9 and the corresponding Grignard reagents followed by substitution of the hydroxyl group with (PhO)(2)P(=O)N-3. The desired diols 7a-c were obtained with higher selectivities of > 7:1 when dihydroxylation of 6a-c was carried out at 0degreesC with OsO4 (catalyst) and NMO in a mixed solvent of MeCN, THF, t-BuOH, and H2O. Among them, the furyl compound recorded the highest selectivity of 14:1. The furyl and azido groups on diol 7a were converted into hydroymethyl and adeninyl groups, respectively, to produce acetonide 2, which upon hydrolysis affords aristeromycin 1.
PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER